UNSPSC 51292208: Mosapride citrate

This classification denotes an antidepressant agent with the molecular formula C21H25ClFN3O3.C6H8O7, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier MF497J489P, chemically known as (+/-)-4-amino-5-chloro-2-ethoxy-n-((4-(p-fluorobenzyl)-2-morpholinyl)methyl)benzamide citrate, but more generally known as mosapride citrate, which bears US NIH Compound Identifier 119583. European Medicines Agency schedules mosapride citrate or its base in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09074MIG.

Most nations, for tariff purposes, schedule mosapride citrate under HS 29349990. SMILES: CCOC1CC(C(CC1C(=O)NCC2CN(CCO2)CC3CCC(CC3)F)CL)N.C(C(=O)O)C(CC(=O)O)(C(=O)O)O.

UNSPSC 51292208 Mosapride citrate, a Commodity code, shows minimal alignment with recent state and local procurement activity. The three opportunities posted under this code in the past four months target naloxone and drug deactivation systems, therapeutic pharmacy benefit programs, and generic multi-source pharmaceuticals with over-the-counter products—none of which are mosapride citrate, a gastrointestinal prokinetic agent. The code mismatch suggests either a data-entry error in the tagging systems or a fundamental disconnect between the nominal product code and the actual work being solicited.

No state or local procurement activity for mosapride citrate itself appears in recent solicitations. The opportunities identified in the search results—Seminole County's naloxone and safe drug deactivation procurement (IFB60459723LAS, response due July 26, 2023); Texas Health and Human Services Commission's Therapeutic Pharmacy Initiative direct-to-manufacturer RFI (HHS0017013, response due April 3, 2026); and Minnesota Multistate Cooperative Purchasing Alliance's generic multi-source pharmaceuticals and OTC products RFP (S1070000015802, response due March 26, 2026)—represent emergency response supplies, pharmacy benefit innovation, and broad pharmaceutical distribution rather than a specific gastrointestinal medication. Unless the code designation is corrected to align with the actual pharmaceutical procurement landscape, firms should treat this code as inactive for state and local contract pursuit.